In May 2003, Dr. Monahan was presented with the 18th Annual Clinical Investigation Program Award for his project entitled, A Pilot Study of Oxaliplatin and Capecitibine in Adult Patients with Refractory Solid Tumors.
Cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer (mCRC), in combination with chemotherapy, and as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.